Project Grant R43HL136220

This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $301,224 to PGXL Technologies LLC, a minority-owned for-profit company, to develop a urine-based, multiplex immunoassay for screening children for obstructive sleep apnea (OSA). The goal is to advance the development of this non-invasive diagnostic technology through initial clinical validation. The project will integrate assays for the...

This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), will fund the development and validation of a novel wearable sensor system called "SleepTronix" to comprehensively assess sleep, breathing patterns, and circadian rhythms in individuals with obstructive sleep apnea (OSA). The $253,500 award will be used to refine the SleepTronix system, which monitors physiological signals such as EEG,...

The National Heart, Lung, and Blood Institute (NHLBI), a division of the National Institutes of Health (NIH), awarded a $1,231,242 Project Grant under the Cardiovascular Diseases Research (CFDA 93.837) program to Powell Mansfield, Inc. for the "BREATH: Breakthrough Research in Electromyography for the Assessment of Sleep-Disordered Breathing" project. This 12-month project aims to develop and validate a diagnostic tool called Deep Learning-Enhanced Transmembranous Electromyography...

This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research (CFDA 93.837) federal grant program, supports the development of an innovative urine-based diagnostic test for obstructive sleep apnea (OSA) in children. The awardee, PGXL Technologies LLC, is a minority-owned for-profit company focused on creating advanced biomarker-based diagnostic technologies. The $128,047 award will enable PGXL Technologies, in collaboration with...

This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research CFDA program (93.837), aims to improve the diagnosis of obstructive sleep apnea (OSA) in primary care clinics. The $740,271 grant, awarded on August 15, 2024, will fund a study to determine the prevalence of undiagnosed OSA and identify barriers to OSA diagnosis in primary care settings. The research will involve two stages: 1) epidemiological assessment of...

This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $711,226 to the University of California, Los Angeles (UCLA) to conduct research on the impact of obstructive sleep apnea (OSA) on the brain. The key objectives are to: 1) examine regional brain temperatures in OSA patients versus healthy controls using 3D echo planar spectroscopic imaging (3D EPSI); 2) assess whole-brain metabolites...

This $332,862 federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports a study to assess night-to-night variability in novel obstructive sleep apnea (OSA) severity metrics and their impact on daytime functioning. The study will leverage cutting-edge sleep monitoring technology and ecological momentary assessments to enroll 300 participants (100 men, 200 women) from two sleep medicine...

The National Heart, Lung, and Blood Institute (NHLBI) awarded a $162,728 Project Grant (CFDA 93.837 - Cardiovascular Diseases Research) to the University of California, San Diego to conduct a mechanistic study on the underlying cardiovascular impacts of overlap syndrome - patients with comorbid obstructive sleep apnea (OSA) and chronic obstructive pulmonary disease (COPD). The 2.5-year grant, effective January 1, 2025 through August 15, 2027, aims to evaluate how right and left heart...

This $1,420,164 Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports research to simultaneously evaluate brain oxygen metabolism and upper airway anatomy in patients with obstructive sleep apnea (OSA). The key objectives are to: 1) optimize an MRI protocol to monitor metabolic and structural changes during induced apneas; 2) examine how OSA disease severity impacts oxygen metabolism and airway anatomy in patients during...

The National Heart, Lung, and Blood Institute (NHLBI) awarded a $426,717 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to The University of Iowa to develop a novel 3D dynamic MRI (3D-DMRI) scheme for quantifying airway collapse in patients with obstructive sleep apnea (OSA). The project aims to: Develop and validate the 3D-DMRI scheme on a cohort of OSA patients being screened for hypoglossal nerve stimulation (HNS) therapy. Develop a deep learning-based...